Sec Form 13G Filing - Oxford Science Enterprises plc filing for Barinthus Biotherapeutics plc. (BRNS) - 2022-02-11

Insider filing report for Changes in Beneficial Ownership

  • Schedule 13G & 13D forms are used to report a party's ownership of stock which exceeds 5% of a company's total stock issue.
  • Schedule 13G is a shorter version of Schedule 13D with fewer reporting requirements.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE 13G

 

 

Under the Securities Exchange Act of 1934

 

(Amendment No. __)*

 

Vaccitech plc
(Name of Issuer)
 
ADS, each representing one ordinary share 
(Title of Class of Securities)
 
   91864C107  
(CUSIP Number)
 
 31 December 2021
(Date of Event Which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

oRule 13d-1(b)

 

oRule 13d-1(c)

 

xRule 13d-1(d)

 

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 1 
 

 

CUSIP No .   91864C107   Page 2 of 4

 

1

NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NO. OF ABOVE  PERSONS (ENTITIES ONLY) 

 

 

Oxford Science Enterprises plc

No I.R.S. Identification Number

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

 

 

 

(a) o

(b) o

3

SEC USE ONLY

 

 
4

CITIZENSHIP OR PLACE OF ORGANIZATION 

 

 England, United Kingdom
 
NUMBER OF
SHARES
BENEFICIALLY
OWNED
BY EACH
REPORTING
PERSON
WITH:

 
5 SOLE VOTING POWER  8,797,770
6 SHARED VOTING POWER  0
7 SOLE DISPOSITIVE POWER  8,797,770
8 SHARED DISPOSITIVE POWER  0
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING
PERSON
 8,797,770
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES
CERTAIN SHARES
o
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9   25.22%
12 TYPE OF REPORTING PERSON   CO

 

 2 
 

 

 Item 1.

 

(a) Name of Issuer: Vaccitech plc

(b) Address of Issuer's Principal Executive Offices: The Schrodinger Building, Heatley Road, The Oxford Science Park, Oxford OX4 4GE, United Kingdom

 

Item 2.

 

(a) Name of Person Filing: Oxford Science Enterprises plc

(b) Address of Principal Business Office or, if none, Residence: 46 Woodstock Road, Oxford OX2 6HT, United Kingdom

(c) Citizenship: England, United Kingdom

(d) Title of Class of Securities: ADS, each representing one ordinary share

(e) CUSIP Number: 91864C107

 

Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: Not Applicable.

 

  (a) o A broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
  (b) o A bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
  (c) o An insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
  (d) o An investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).;
  (e) o An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
  (f) o An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
  (g) o A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
  (h) o A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
  (i) o A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
  (j) o A non-U.S. institution in accordance with § 240.13d–1(b)(1)(ii)(J; and
  (k) o A group, in accordance with §240.13d–1(b)(1)(ii)(K). ). If a member of the group is filing as a non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J), please specify the type of institution:
 

 

Item 4. Ownership.

 

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

 

(a) Amount beneficially owned: 8,797,770

(b) Percent of class: 25.22%

(c) Number of shares as to which the person has:

(i)     Sole power to vote or to direct the vote: 8,797,770

(ii)    Shared power to vote or to direct the vote: 0

(iii)   Sole power to dispose or to direct the disposition of: 8,797,770

(iv)   Shared power to dispose or to direct the disposition of: 0

 

 3 
 

 

Item 5. Ownership of Five Percent or Less of a Class

 

Not Applicable.

 

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

 

Not Applicable.

 

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

 

Not Applicable. 

 

Item 8. Identification and Classification of Members of the Group

 

Not Applicable.

 

Item 9. Notice of Dissolution of Group

 

Not Applicable.

 

Item 10. Certification

 

Not Applicable.

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Date: February 11, 2022

 

 

 

  Oxford Science Enterprises plc
     
     
     
  By:  /s/ Jim Wilkinson  
  Name: Jim Wilkinson  
  Title: Chief Financial Officer  

 

 

4